Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Optimal duration of neoadjuvant androgen deprivation therapy for prostate volume reduction in locally advanced prostate cancer radiotherapy

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Puneet Bagri

Citation

Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524

Authors

S. Samdariya, P.K. Bagri, P. Pareek

Author affiliations

  • Radiation Oncology, All India Institute Of Medical Sciences(AIIMS), 342005 - Jodhpur/IN
More

Resources

Aim/Background

In locally advanced prostate cancer, the results of radiotherapy are improved by combination with androgen deprivation therapy. Prostate volume reduction by neoadjuvant hormonal treatment can facilitate dose escalation without increasing the toxicity. The aim of this study is to decide the optimal duration of neoadjuvant androgen deprivation therapy for prostate volume reduction in locally advanced prostate cancer patients scheduled for external beam radiotherapy (EBRT).

Methods

Eighteen patients scheduled for external beam radiotherapy with locally advanced prostate cancer (cT2-3N0/xM0) were treated with a nonsteroidal anti-androgen (Bicalutamide) for 9 months in neoadjuvant setting. Repeated CT scan examination was performed 3-monthly to measure prostate volumes until the start of EBRT.

Results

The baseline median prostate volume for enrolled patients was 78cc (95% CI: 58–97cc) with a median volume reduction of 29% (95% CI: 24%–35%) (P <0.0001) after 3 months of bicalutamide. Between 3 and 6 months, a median volume reduction of 11% (95% CI: 6%–15%) (P <0.0001) was observed. No significant volume reduction occurred between 6 and 9 months of hormonal treatment.

Conclusions

In this study, the most significant prostate volume reduction is achieved after 3 months of hormonal treatment with a maximum reduction after 6 months. Therefore, the optimal duration of neoadjuvant androgen deprivation to reduce prostate volume before prostate cancer radiotherapy is 6 months.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings